1 0 6 0 VOLUME 18 | NUMBER 7 | JULY 2012 nAture medicine [1] [2] [3] [4] [5] . In contrast, the contribution of cells at the interface between innate and adaptive immunity, such as NKT cells, remains controversial 6 . NKT cells respond in a T cell receptor (TCR)-restricted manner to lipid antigens presented by CD1d on professional and nonprofessional antigen-presenting cells and show pronounced cytokine secretion within hours of cognate antigen recognition, which enables broad effects on activation of other innate (NK) and adaptive (T and B) immune cells 7, 8 . Given the central role of NKT cells in both direct and indirect modulation of the immune system, NKT cells have been shown to be crucial in the defense against a variety of microbial pathogens 8 . Analysis of liver gene expression in chimpanzees 2 weeks after HBV infection has shown evidence for a lack of induction of immunerelated genes, suggesting that HBV acts a stealth virus that escapes innate immune responses during early infection 9 . However, studies in HBV-infected humans and chimpanzees have demonstrated the presence of HBV-specific T and B cells within weeks of infection, consistent with successful priming of an adaptive immune response 1,10,11 . These observations suggest that HBV might be susceptible to recognition by the immune system directly after infection. Accordingly, recent studies in animal models of Hepadnaviridae infection and in HBV-infected humans have shown activation of NKT cells at very early time points following infection 10-12 . Thus, infection of woodchucks with woodchuck hepatitis virus led to hepatic NKT cell infiltration within 48 h, which correlated with interferon-γ (IFN-γ) secretion and temporary suppression of viral replication 12 . These findings are consistent with the observation that pharmacological stimulation of invariant NKT (iNKT) cells, a subset of NKT cells defined by expression of the Vα14-Jα18 TCR in mice and Vα24-Jα18 TCR in humans, leads to rapid IFN-γ-dependent inhibition of viral replication in transgenic mice expressing replication-competent HBV genomes 13 . Similarly, a study of humans during the incubation phase of HBV infection showed increased levels of peripheral NK cells consistent with innate immune activation early after HBV infection 11 . Most notably, a recent report on two humans with HBV demonstrated very early activation of peripheral natural T cells, a population of cells that phenotypically resemble classical NKT cells. Natural T cell activation preceded activation of NK and conventional T cells and was associated with subsequent control of HBV infection 10 . These studies demonstrate a correlation between viral control and NKT cell activation. To investigate whether NKT cells are an important checkpoint that contributes to control of HBV infection, we studied various in vitro and in vivo models of HBV infection. In most adult humans, hepatitis B is a self-limiting disease leading to life-long protective immunity, which is the consequence of a robust adaptive immune response occurring weeks after hepatitis B virus (HBV) infection. Notably, HBV-specific T cells can be detected shortly after infection, but the mechanisms underlying this early immune priming and its consequences for subsequent control of viral replication are poorly understood. Using primary human and mouse hepatocytes and mouse models of transgenic and adenoviral HBV expression, we show that HBV-expressing hepatocytes produce endoplasmic reticulum (ER)-associated endogenous antigenic lipids including lysophospholipids that are generated by HBV-induced secretory phospholipases and that lead to activation of natural killer T (NKT) cells. The absence of NKT cells or CD1d or a defect in ER-associated transfer of lipids onto CD1d results in diminished HBV-specific T and B cell responses and delayed viral control in mice. NKT cells may therefore contribute to control of HBV infection through sensing of HBV-induced modified self-lipids. 
Conventional T and B cells have a crucial role in HBV infection
. In contrast, the contribution of cells at the interface between innate and adaptive immunity, such as NKT cells, remains controversial 6 . NKT cells respond in a T cell receptor (TCR)-restricted manner to lipid antigens presented by CD1d on professional and nonprofessional antigen-presenting cells and show pronounced cytokine secretion within hours of cognate antigen recognition, which enables broad effects on activation of other innate (NK) and adaptive (T and B) immune cells 7, 8 . Given the central role of NKT cells in both direct and indirect modulation of the immune system, NKT cells have been shown to be crucial in the defense against a variety of microbial pathogens 8 .
Analysis of liver gene expression in chimpanzees 2 weeks after HBV infection has shown evidence for a lack of induction of immunerelated genes, suggesting that HBV acts a stealth virus that escapes innate immune responses during early infection 9 . However, studies in HBV-infected humans and chimpanzees have demonstrated the presence of HBV-specific T and B cells within weeks of infection, consistent with successful priming of an adaptive immune response 1, 10, 11 . These observations suggest that HBV might be susceptible to recognition by the immune system directly after infection. Accordingly, recent studies in animal models of Hepadnaviridae infection and in HBV-infected humans have shown activation of NKT cells at very early time points following infection [10] [11] [12] . Thus, infection of woodchucks with woodchuck hepatitis virus led to hepatic NKT cell infiltration within 48 h, which correlated with interferon-γ (IFN-γ) secretion and temporary suppression of viral replication 12 . These findings are consistent with the observation that pharmacological stimulation of invariant NKT (iNKT) cells, a subset of NKT cells defined by expression of the Vα14-Jα18 TCR in mice and Vα24-Jα18 TCR in humans, leads to rapid IFN-γ-dependent inhibition of viral replication in transgenic mice expressing replication-competent HBV genomes 13 . Similarly, a study of humans during the incubation phase of HBV infection showed increased levels of peripheral NK cells consistent with innate immune activation early after HBV infection 11 . Most notably, a recent report on two humans with HBV demonstrated very early activation of peripheral natural T cells, a population of cells that phenotypically resemble classical NKT cells. Natural T cell activation preceded activation of NK and conventional T cells and was associated with subsequent control of HBV infection 10 . These studies demonstrate a correlation between viral control and NKT cell activation. To investigate whether NKT cells are an important checkpoint that contributes to control of HBV infection, we studied various in vitro and in vivo models of HBV infection.
RESULTS

Early activation of NKT cells in response to Ad-HBV
To study NKT cell responses, we investigated a mouse model that overcomes the nonpermissiveness of mouse hepatocytes to HBV through adenoviral delivery of a replication-competent HBV genome under the control of its endogenous promoters [14] [15] [16] . Injection of 1 × 10 9 HBV-expressing adenoviral particles (Ad-HBV), a dose shown by us (Supplementary Fig. 1a ) and others 16 to induce an immune response against HBV but not the adenoviral carrier, led to HBV replication ( Supplementary Fig. 1b) followed by a rapid drop in hepatic HBV DNA and serum HBV surface antigen (HBsAg) that preceded hepatitis ( Supplementary Fig. 1b,c) . A control adenovirus expressing β-galactosidase (Ad-LacZ) did not lead to hepatitis, confirming HBV-dependent inflammation ( Supplementary  Fig. 1a ) [14] [15] [16] . As Ad-HBV infection in mice resembles the course of natural HBV infection in humans 17 , we further studied NKT cell responses in this model. Notably, the entire population of liver but not splenic iNKT cells showed activation and IFN-γ secretion as early as 1 d after Ad-HBV but not Ad-LacZ administration and thus before histological inflammation and the rise in serum alanine aminotransferase (ALT) levels (Fig. 1a-c and Supplementary Fig. 2 ). Similar to iNKT cells, hepatic but not splenic noninvariant NKT cells, an NKT cell population expressing a rather diverse set of TCRs that were detected by a reporter model developed for these studies (see Supplementary Data and Supplementary Fig. 3 ), showed pronounced activation and IFN-γ secretion in response to Ad-HBV (Fig. 1d-f and Supplementary  Fig. 4 ). In contrast, activation of NK and T cells was not observed until 3 d after Ad-HBV challenge (Fig. 1g-i and data not shown) and thus followed activation of NKT cells, similar to observations in patients with HBV 10 .
NKT cells contribute to the immune response against HBV To investigate whether NKT cells contribute to innate and adaptive immune responses against HBV, we analyzed activation of liver mononuclear cells (LMNCs) in response to Ad-HBV in mice lacking invariant NKT cells (Jα18-deficient mice) or all NKT cells (CD1d-deficient mice). In wild-type mice, hepatic NK, CD4 + and CD8 + T cells showed strong activation and IFN-γ secretion in response to infection with Ad-HBV, but not Ad-LacZ (Fig. 1g-i and data not shown). In contrast, CD1d-deficient mice showed significantly diminished NK, CD4 + and CD8 + T cell activation, whereas Jα18 deficiency predominantly affected CD4 + T cell activation (Fig. 1g-i ). Viral transduction of hepatocytes was similar in all mouse strains (Supplementary Fig. 5 ).
NKT-dependent activation was also observed for HBV-specific CD8 + T cell responses among liver mononuclear cells (LMNCs) against envelope (HBsAg, S, amino acids 190-197; VWLSVIWM) and HBV core (HBcAg, C, amino acids 93-100; MGLKFRQL) antigens analyzed ex vivo but not in response to phytohemagglutinin ( Fig. 2a and Supplementary Fig. 6a,b) . Analysis of LMNC responses to pools of peptides spanning the entire HBV envelope 18 revealed pronounced defects in the magnitude but not diversity of HBV-specific CD8 + T cell responses in HBV envelope-transgenic × Rag1 −/− × CD1d-deficient mice (HBVEnv Rag1 −/− CD1d-deficient mice) that received, by adoptive transfer, wild-type splenocytes ( Fig. 2b and  Supplementary Fig. 6c ). The adaptive immune defects extended to B cells, as levels of HBsAg-specific antibodies were lower in Ad-HBV-challenged CD1d-deficient and Jα18-deficient mice compared to wild-type mice (Fig. 2c) and in HBVEnv Rag1 −/− CD1d-deficient mice compared to HBVEnv Rag1 −/− mice (Fig. 2d) , resulting in lack of sustained HBsAg clearance from serum (Fig. 2e) . These data show that NKT cells contribute to activation of NK, T and B cells in different HBV mouse models.
In accordance with a central role of NKT cells in HBV-induced hepatitis 19, 20 , CD1d-deficient and Jα18-deficient mice showed reduced peak levels of serum ALT (Fig. 2f) , liver IFN-γ (Fig. 2g) and hepatic immune cell infiltration (data not shown). However, CD1d-deficient and Jα18-deficient mice developed chronic lowgrade inflammation that persisted at least to day 30 ( Fig. 2f,h) , the end of the observation period. This was associated with delayed clearance of serum HBsAg (Fig. 2i) and serum and liver HBV DNA a 1,500 P = 0.03
2,500 P = 0.01 P = 0.04 P = 0.01 800 
npg
( Fig. 2j and Supplementary Fig. 7d,e) , consistent with defects in viral control leading to chronic inflammation. Consistent with a crucial role of CD8 + T cells in the antiviral response against HBV 1 , NKT cells were necessary but not sufficient for viral control, as Tap1 −/− mice lacking CD8 + T cells also showed severe defects in HBV clearance (Supplementary Fig. 7 ). These results show that NKT cells contribute to the initiation of antiviral immune responses against HBV and to viral control and prevention of chronic viral replication in the Ad-HBV model.
HBV-infected human and mouse hepatocytes activate NKT cells
To identify the cell type responsible for NKT cell activation upon Ad-HBV challenge, we studied activation of NKT cell hybridomas in response to T cell-depleted liver and spleen mononuclear cells and primary hepatocytes obtained from Ad-HBV-infected mice. Ad-HBV-transduced hepatocytes but not T cell-depleted mononuclear cells induced activation of NKT cells (Fig. 3a, Supplementary Fig. 8a and data not shown). We observed similar activation of NKT cells upon in vitro exposure of primary hepatocytes to Ad-HBV (Supplementary  Fig. 8b ; for purity and transduction of primary hepatocytes see Supplementary Fig. 9) .
NKT activation by Ad-HBV-infected hepatocytes was CD1d restricted (Fig. 3b) and limited to NKT cells, as demonstrated by unaffected major histocompatibility complex (MHC) class I presentation and CD8 + T cell activation (Fig. 3c) . Activation was specific for a subset of invariant (24.7 cell line) and noninvariant (14S.6 cell line) mouse NKT cell hybridomas (Fig. 3a) and could also be demonstrated with human primary hepatocytes infected with Ad-HBV or a primary (nonadenoviral) HBV isolate (Fig. 3d,e) . These data reveal an unanticipated role of hepatocytes in HBV-dependent NKT cell activation.
NKT cell activation is dependent on lipid transfer
Microsomal triglyceride transfer protein (MTP) is an ER-resident protein that transfers endogenous phospholipids onto CD1d and is crucial for CD1d function [21] [22] [23] [24] [25] . To delineate the role of hepatocyte MTP and CD1d in Ad-HBV infection, we generated mice with hepatocyte-specific deletion of Mttp, which codes for MTP (H-Mttp −/−26 , Supplementary Fig. 10a ). MTP deficiency led to severe defects in the presentation of endogenous and exogenous lipid antigens that were specific for hepatocytes and limited to CD1d ( Supplementary Fig. 10b- 
e).
Consistent with a key role of MTP in HBV-induced and CD1d-restricted antigen presentation, primary hepatocytes from H-Mttp −/− mice showed impaired activation of NKT cells in response to Ad-HBV in vitro (Fig. 3f,g and Supplementary Fig. 10 ). We made similar observations upon chemical inhibition of MTP ( Supplementary  Fig. 11 ) and in human hepatocytes infected with a primary HBV isolate (Fig. 3e) . These results were confirmed by in vivo experiments, in which NKT cells from Ad-HBV-challenged H-Mttp −/− mice showed reduced activation and impaired IFN-γ secretion (Fig. 1a-c) . Accordingly, NKT cell-dependent activation of NK cells and HBVspecific T and B cells was impaired in H-Mttp −/− mice ( Fig. 1g-i,  Fig. 2a,c and Supplementary Fig. 6a ). H-Mttp −/− mice showed diminished acute hepatitis, delayed viral control and chronic low-grade inflammation upon Ad-HBV challenge ( Fig. 2 and Supplementary  Fig. 7 ). These data confirm that hepatocytes are the antigen-presenting cells responsible for NKT cell activation and show that this effect is dependent upon hepatocyte expression of MTP and CD1d.
Alterations in hepatocyte lipids upon Ad-HBV infection
Ad-HBV-induced NKT cell activation was not the consequence of altered CD1d expression or trafficking ( Supplementary Fig. 12a,b) .
10,000 P = 0.008 44 (h, day 30 after virus injection), serum HBsAg (i) and serum HBV DNA (j, day 7 after virus injection). In f and i, significance levels as indicated by asterisks (*P < 0.05, **P < 0.01, ***P < 0.001) reflect from top to bottom Jα18 KO, CD1d KO, H-Mttp KO versus control wild-type mice at each relevant time point. Mean ± s.e.m. is shown in all panels (6-8 mice per group). Results are representative of two independent experiments. npg Similarly, iNKT cell activation by hepatocytes loaded with the exogenous model lipid α-galactosylceramide (αGalCer) was not affected by Ad-HBV (Supplementary Fig. 12c ). Given that nucleocapsid-free subviral HBsAg particles, which are produced at considerably higher numbers compared to complete HBV virions 27 , bud at ER and Golgi membranes 28 and selectively recruit ER lipids for their envelopes 29 , we investigated whether HBV-induced NKT activation is the consequence of alterations in endogenous ER-acquired CD1d lipids. We studied activation of NKT hybridomas in response to platebound CD1d loaded with lipids obtained from Ad-HBV-infected primary mouse hepatocytes. We found that even uninfected primary hepatocytes contained antigenic CD1d lipids that were enriched in microsomal ER preparations (Supplementary Fig. 13a-e) . However, microsomes from Ad-HBV-but not Ad-LacZ-transduced hepatocytes showed significantly increased activation of invariant and noninvariant NKT cell hybridomas (Fig. 4a,b) compared to microsomes from uninfected hepatocytes. Microsomal lipids obtained from CD1d-deficient and H-Mttp −/− hepatocytes showed similar NKT cell activation ( Supplementary Fig. 13f and data not shown), indicating that antigenic lipids were unable to be loaded onto (H-Mttp −/− ) or presented by (CD1d-deficient mice) CD1d. Accordingly, purified MTP enhanced presentation of immunogenic Ad-HBV-dependent lipids (Fig. 4c) .
Only a subset of NKT cell hybridomas recognized Ad-HBVinfected hepatocytes (Fig. 3a) . Given that the TCRαβ repertoire of these hybridomas is unlikely to reflect that of liver NKT cells in vivo 30 , we investigated the response of primary liver-derived NKT cells to hepatocyte microsomal lipids. A significant population of sorted noninvariant liver NKT cells recognized Ad-HBV-induced alterations in microsomal lipids, as determined by upregulation of CD69 expression (Fig. 4d,e) . CD69 upregulation was less pronounced for sorted iNKT cells, suggesting that iNKT cell responses to Ad-HBV are either restricted to a subpopulation of these cells or that iNKT cells are broadly but less strongly activated by Ad-HBV (Fig. 4d,e) . In conclusion, exposure to Ad-HBV is associated with increased antigenicity of ER lipids, which are recognized by NKT cells.
Ad-HBV induces antigenic lysophosphatidylethanolamine
To characterize Ad-HBV-dependent lipid alterations, we separated microsomal lipids obtained from hepatocytes according to solubility 31 . Ad-HBV-induced stimulatory fractions for noninvariant and invariant NKT cells were both recovered in phospholipid-enriched methanol eluents, but subfractionation indicated that the two NKT cell subtypes were activated by different lipids (Fig. 4f,g ). To characterize the particular lipids induced by Ad-HBV and stimulatory for NKT cells, we screened methanol fractions by HPLC mass spectrometry (HPLC-MS). Previous reports demonstrated selective recruitment of ER lipids by HBV subviral particles and underrepresentation of phosphatidylethanolamine (PE) species in the HBV envelope 29 . Comparison of chromatograms corresponding to the mass and collisional spectra of diacyl PE showed strong enrichment of PE and lysophosphatidylethanolamine (lysoPE) after Ad-HBV exposure (Supplementary Fig. 14) . Lysophospholipids have recently been shown to be antigenic endogenous CD1d ligands in human cells in vitro 32, 33 . Therefore, we rescreened stimulatory fractions at masses corresponding to monoacyl PE species with C16, C18:2, C18:1 and C18 monacyl forms and found in all cases that these lipids were upregulated after Ad-HBV administration in vivo (Fig. 5a) . Thus, there is an overlap among the types of lipids upregulated in response to Ad-HBV and lysophosopholipids that can stimulate NKT cells.
To further test initial conclusions derived from complex cellular lipid mixtures generated in vivo, we tested activation of mouse NKT 14S.6, a noninvariant NKT cell hybridoma that responded to Ad-HBV (Fig. 3a) , showed activation in response to lysoPE and lysophosphatidylcholine (lysoPC) species containing hydrocarbon chains with lengths of 16 and 18 carbons (Fig. 5b) . As hepatocyte lysoPE but not lysoPC abundance was increased in response to Ad-HBV (Supplementary Fig. 14) , only lysoPE is implicated in the response to Ad-HBV. NKT cell activation by lysoPE was, among hybridomas, specific for 14S.6 and not observed with other iNKT hybridomas (24.7, 24.8, 24.9 or DN32.D3) or noninvariant NKT hybridomas (14S.7, 14S.10 or 14S.15; Fig. 5b and data not shown) . Lyso-PE-induced NKT activation required plate-bound CD1d (data not shown), and purified MTP facilitated lysoPE presentation (Fig. 5c) . These results extended to primary NKT cells, as >50% of sorted noninvariant liver NKT cells obtained from IL-4-IRES-GFP-enhanced transcript (4Get) × Jα18-deficient mice liver NKT cells showed upregulation of CD69 expression in response to lysoPE but not PE (Fig. 5d) . Noninvariant NKT cell activation was not limited to cells expressing Vβ14, the TCRβ chain shared by the noninvariant NKT hybridoma (14S.6) that recognized lysoPE (Fig. 5d) . This suggests that lysoPE broadly activates noninvariant NKT cells in the liver and further reiterates the limited overlap between currently available NKT hybridomas and primary NKT cells in vivo. In contrast, iNKT cells did not show activation in response to lysoPE (Fig. 5d) .
NKT cell activation is dependent on secretory phospholipases Secretory phospholipase A 2 (sPLA 2 ) enzymes contribute to the generation of lysophospholipids recognized by NKT cells and are active within secretory compartments 33, 34 . We therefore investigated the role of sPLA 2 in Ad-HBV-dependent NKT cell activation. Chemical inhibitors of sPLA 2 but not cytoplasmic PLA 2 (cPLA 2 ) prevented HBV-dependent activation of noninvariant NKT cells without affecting MHC class I presentation ( Fig. 5e and Supplementary Fig. 15a-g ). sPLA 2 inhibitors also did not affect iNKT cells, in accordance with the lack of lysoPE-dependent iNKT activation (Fig. 5f) .
As Ad-HBV-transduction of hepatocytes leads to increased abundance of PE (Supplementary Fig. 14b ), the substrate for PLA 2 -mediated production of lysoPE, we investigated hepatocyte gene expression of sPLA 2 (gene names listed in Fig. 5g) , cPLA 2 (Pla2g4a) and calcium-independent PLA 2 (iPLA 2 , Pla2g6a) enzymes. Ad-HBV led to rapid and selective upregulation of sPLA 2 enzymes Pla2g2c and Pla2g5 but not other sPLA 2 , cPLA 2 and iPLA 2 enzymes in vivo ( Fig. 5g and Supplementary Fig. 16a ). These results are in accordance with increased hepatic PLA 2 group II and V expression in patients with viral hepatitis 35, 36 . Primary mouse hepatocytes also showed Ad-HBV-induced Pla2g2c upregulation, confirming hepatocytespecific effects and demonstrating that sPLA 2 regulation is not secondary to hepatic inflammation but a direct consequence of exposure to Ad-HBV (Supplementary Fig. 16b ). Primary human hepatocytes exposed to Ad-HBV or a primary HBV isolate also showed upregulation of sPLA 2 , specifically of PLA2G2A (Fig. 5h) . As lysoPE activates transcription of PLA2G2A 37 , it most likely supports its own production through a positive-feedback loop involving sPLA 2 . Thus, HBV leads to upregulation of sPLA 2 group II in mouse and human hepatocytes. Specific subgroups of sPLA 2 differ between humans and mice npg in accordance with differences in the genomic organization of sPLA 2 loci (PLA2G2C is a pseudogene in humans 38 ; Pla2g2a is inactivated by a frameshift in C57BL/6J mice). Consistent with a crucial role for sPLA 2 in HBV-dependent generation of lysophospholipids as major antigens recognized by noninvariant NKT cells, siRNA directed against Pla2g2c and Pla2g5 (Supplementary Fig. 17a ) but not the genes encoding other sPLA 2 , cPLA 2 and iPLA 2 enzymes prevented Ad-HBV-induced activation of noninvariant NKT but not invariant NKT cells or MHC class I-restricted T cells (Fig. 5i,j and Supplementary Fig. 17b and data not shown).
HBsAg contributes to NKT cell activation
To investigate the requisite HBV element for NKT cell activation, we inactivated individual HBV open reading frames and studied the effects on NKT activation. Although all viral mutants showed similar transduction rates (Supplementary Figs. 5 and 9) , only deletion of the small HBsAg (HBsAg S − ), which is required for viral secretion, led to impaired activation of noninvariant NKT cells (Fig. 6a) . We observed a similar but nonsignificant trend for iNKT cells (Fig. 6b) . Ad-HBV S − led to impaired hepatocyte sPLA 2 upregulation and impaired activation of noninvariant NKT cells by microsomal hepatocyte lipids ( Fig. 6c and Supplementary Fig. 16c) .
To extend these findings, we examined mice transgenically expressing HBsAg 19 . HBsAg-transgenic mouse hepatocytes led to CD1d-dependent activation of noninvariant and invariant NKT cell hybridomas but not MHC class I-restricted T cell hybridomas (Fig. 6d-f) . In addition, microsomal lipids of HBsAg-transgenic hepatocytes activated NKT cells (Fig. 6g,h) . In vivo administration of Ad-HBV S − resulted in prolonged chronic necroinflammation and delayed viral control in association with sustained viral replication and impaired hepatic IFN-γ induction ( Supplementary  Fig. 18 ). These studies show that the small HBsAg contributes to Ad-HBV-mediated activation of NKT cells, which is in accordance with a temporal association between HBsAg expression and early NKT cell activation in human HBV infection 10 . iNKT cell activation in vivo is cytokine dependent Primary liver iNKT cells were not activated by lysoPE (Fig. 5d) and showed less robust activation in response to Ad-HBV microsomal lipids (Fig. 4d) . We therefore investigated whether cytokine-mediated indirect activation contributes to Ad-HBV-induced iNKT cell activation in vivo. Indeed, neutralization of interleukin-12 (IL-12), a cytokine essential for indirect NKT cell activation [39] [40] [41] , largely prevented CD69 upregulation and IFN-γ secretion by iNKT cells but had negligible effects on noninvariant NKT cells (Fig. 6i,j and Supplementary Fig. 19 ). These results suggest that noninvariant NKT cells are directly activated upon Ad-HBV exposure by CD1d-restricted presentation of lysoPE and other uncharacterized hepatocyte antigens. This, in turn, may lead to cytokine-dependent activation of iNKT cells, presumably through activation of liver dendritic cells and macrophages 39, 40 . Notably, IL-12-mediated indirect activation of liver iNKT cells requires hepatocyte MTP (Fig. 1a-c) , suggesting that cytokine-dependent iNKT activation is downstream of CD1d-restricted activation of noninvariant NKT cells and NKT-dependent dendritic cell maturation 42, 43 .
DISCUSSION
The findings presented here show that immune responses provided by NKT cells contribute not only to HBV-induced hepatitis 19 but also to viral control. Although HBV-induced NKT cell activation is associated with acute hepatitis, NKT cells contribute considerably to the emergence of antiviral B and T cell immunity. In the absence of this NKT cell response, adaptive immunity and viral control are diminished and chronic, low-grade hepatitis ensues. We show that the cell type responsible for orchestrating these HBV-induced responses is previously unappreciated and, notably, the infected hepatocyte itself and not a professional antigen-presenting cell. Within the hepatocyte, HBV induces the production of ER lipids, including lysophospholipids derived from PE through the action of HBV-induced secretory phospholipases. CD1d-restricted presentation of lysophospholipids leads to direct activation of noninvariant NKT cells and subsequent IL-12-mediated indirect iNKT cell activation, confirming that both direct and indirect mechanisms contribute to NKT cell activation in vivo 39, 40 .
The generation of antigenic lipids is partially dependent on the presence of the HBV surface antigen, the principal HBV structural npg component responsible for assembling PC-rich particles in the ER, and possibly results from an imbalanced lipid milieu within the ER 29 .
As such, the hepatocyte uses secretory phospholipases, MTP and CD1d to sense the presence of HBV and alert NKT cells through the display of modified self-lipids on the cell surface of the hepatocyte to trigger an adaptive immune response. Our findings of an NKT cell response soon after HBV exposure are in accordance with other recent observations in humans and animal models of HBV [10] [11] [12] and suggest that NKT cells are part of an early, important sensing system that activates the immune response, leading to effective priming of HBV-specific adaptive immune cells that are required for viral clearance. Our data suggest that although HBV acts as a stealth virus during a prolonged phase preceding viral control 9 , it is susceptible to a distinct type of immune recognition directly following infection, which is important for subsequent immune clearance. Further studies in HBV-infected humans are required to confirm a central role of NKT cells in human HBV infection.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
